🏥 Mon–Sat 9AM–5PM 📅 OPD: Mon–Thu 10AM–1PM 📞 0233 221 1779 Contact Us →
📊

Tumour Marker Monitoring

Serial measurement of cancer-specific blood markers — CEA, CA-125, AFP, PSA, b-hCG, LDH — to monitor treatment response and detect recurrence early.

Monitoring Diagnosis CEA PSA CA-125
Tumour markers are proteins or other substances produced by cancer cells that can be detected in the blood. While not diagnostic on their own, serial monitoring of tumour markers provides essential information about treatment response and disease surveillance. At our centre, we arrange and interpret a full range of tumour markers: CEA (colorectal, lung), CA-125 (ovarian), AFP and b-hCG (germ cell tumours), PSA (prostate), CA19-9 (pancreatic/biliary), LDH (lymphoma, testicular), paraprotein/M-band (myeloma), beta-2 microglobulin (lymphoma, myeloma) and BCR-ABL PCR (CML). Markers are trended over time — a rising marker despite treatment may indicate resistance, while a falling marker typically signals response. This data, combined with imaging and clinical assessment, guides all treatment decisions.

📋 Treatment Overview

Type
Tumour Marker Monitoring
Speciality
Oncology & Haematology
Administered By
Dr. Ravindra Joshi

📅 Schedule a Consultation

Talk to Dr. Joshi about whether this treatment is right for you. OPD: Mon–Thu, 10 AM – 1 PM.

Call Now WhatsApp